Q-omics provides the consensus-scored MIR1273H profile across patient tissues and cancer cell-line models. MIR1273H expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR1273H is differentially expressed in 2, with the highest sampling consensus in PAAD. Additionally, MIR1273H RNA expression shows 10,592 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, PAAD, and LSCC as cancer lineages where MIR1273H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1273H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1273H survival associations across molecular data types. MIR1273H RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1273H RNA expression–survival associations across cancer types. High MIR1273H expression shows unfavorable associations in UCS, THCA, KIRC, MESO and CHOL, but favorable associations in SKCM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR1273H RNA expression.
This table summarizes MIR1273H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1273H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1273H shows lower tumor expression in LUSC and higher tumor expression in PAAD. The PAAD box plot shows higher MIR1273H RNA expression in tumor versus normal tissue (log2 FC = +0.830, t-test p = .014).
This table shows molecular features associated with MIR1273H in patient tissues and cancer cell lines. In patient samples, MIR1273H shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
